Piclidenoson

N/A

Report date: 2026/02/25 20:02:36
NME

Base Information

Drug NamePiclidenoson
Drug Alias Namepiclidenosonum匹利诺生匹立迪松CF-101SI-615
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A3 receptor agonists
TargetsAdenosine A3 receptor
Therapy Area/IndicationsPlaque psoriasisCoronavirus Disease 2019 (COVID-19)Psoriasis +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBosnia and HerzegovinaBulgaria +[14] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCan-Fite Biopharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChina Medical System Holdings LtdCan-Fite Biopharma LtdFondazione Telethon
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisCoronavirus Disease 2019 (COVID-19)Psoriasis +[5] 
Inactive IndicationsUveitis, IntermediateUveitis, PosteriorGlaucoma +[8] 

Other Information

ATC CodeN/A
Related LinksN/A